Game Changer Drug For COVID-19: After Glenmark, Hetero Compa
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Dr. B.P RAHUL
Game Changer Drug For COVID-19: After Glenmark, Hetero Company will Supply its “COVIFOR” Drug to many States for COVID-19 Treatment!

DCGI endorsed Hetero Pharmaceuticals for the supply of drug Covifor (Remdesivir) to various states where the many suspected or laboratory-confirmed COVID cases are hospitalized because of drastic symptoms of the Corona virus.

Hetero stated that Covifor (Remdesivir) will be provided in a 100 mg vial (injectable) and must be administered intravenously in a hospital or intensive care unit under the supervision of a healthcare practitioner.

The chairman of the Hetero Group also stated that “with the rising number of COVID-19 cases in the nation, the endorsement for the supply of Covifor (Remdesivir) drug can prove to be a game-changer because clinical results are positive and satisfactory”.

What is Covifor?

Covifor is a generic version of Remdesivir drug which can be used in emergency conditions of Corona cases

It is a drug whose first batch will be supplied to Delhi, Maharastra, Gujrat etc.

The company is sure about enough stock to provide to the present requirements of the drug. 

COVID-19 therapy by Covifor will cost less than 30,000 per patient. Six doses of the drug will be provided in the aforementioned timeframe. 

Dr. M. Srinivasa Reddy stated that “Covifor is Remdesivir’s first generic brand. With this Covifor drug, we hope to lessen the treatment time of patients within the hospital, decreasing the increasing pressure on the medical foundation that’s currently overburdened because of a sudden acceleration in COVID- 19 infection rates”.

He further said that we are working closely with the government and the medical community so that public and private medical institutions across the country can quickly access the “COVIFOR” drug.

In May, the Supreme Drug Regulatory Authority allowed the manufacturing authorization of the antiviral drug Remdesivir to Hetero, Cipla, and other pharmaceutical companies, only for “restricted emergency use” COVID-19 patients with moderate disease (especially those on oxygen).
https://www.inventiva.co.in/trends/tamanna/game-changer-drug-for-covid-19-after-glenmark-hetero-company-will-supply-its-covifor-drug-to-many-states-for-covid-19-treatment/

Preview
Like
Comment
Share